[论文解读] Mathematical Modelling of Allergy and Specific Immunotherapy: Th1-Th2-Treg Interactions

Fridolin Groß, G Metzner+1 more|arXiv (Cornell University)|Mar 4, 2010

Allergic Rhinitis and Sensitization参考文献 17被引用 5

一句话总结

本研究将经典的Th1-Th2数学模型扩展，纳入调节性T细胞（Treg）及其细胞因子，表明过敏原特异性免疫治疗的成功关键在于维持阶段前进行高剂量过敏原注射。模型显示，Treg的扩增和Th2的抑制最有效地由快速、高剂量的抗原暴露触发，解释了为何快速（rush）治疗方案相比传统方案能更早产生治疗效果。

ABSTRACT

Regulatory T cells (Treg) have recently been identified as playing a central role in allergy and during allergen-specific immunotherapy. We have extended our previous mathematical model describing the nonlinear dynamics of Th1-Th2 regulation by including Treg cells and their major cytokines. We hypothesize that immunotherapy mainly acts on the T cell level and that the decisive process can be regarded as a dynamical phenomenon. The model consists of nonlinear differential equations which describe the proliferation and mutual suppression of different T cell subsets. The old version of the model was based upon the Th1-Th2 paradigm and is successful in describing the "Th1-Th2 switch" which was considered the decisive event during specific immunotherapy. In recent years, however, the Th1-Th2 paradigm has been questioned and therefore, we have investigated a modified model in order to account for the influence of a regulatory T cell type. We examined the extended model by means of numerical simulations and analytical methods. As the modified model is more complex, we had to develop new methods to portray its characteristics. The concept of stable manifolds of fixed points of a stroboscobic map turned out to be especially important. We found that when including regulatory T cells, our model can describe the events in allergen-specific immunotherapy more accurately. Our results suggest that the decisive effect of immunotherapy, the increased proliferation of Treg and suppression of Th2 cells, crucially depends on the administration of high dose injections right before the maintenance phase sets in. Empirical protocols could therefore be improved by optimizing this step of therapy.

研究动机与目标

• 为解决经典Th1-Th2范式在解释过敏原特异性免疫治疗时的局限性，引入调节性T细胞（Treg）。
• 利用非线性微分方程，建立Th1、Th2与Treg细胞之间动态相互作用的数学模型。
• 研究不同临床方案（传统 vs. 快速）对免疫耐受诱导时机与疗效的影响。
• 识别Treg介导的Th2反应抑制最有效启动的治疗关键阶段。
• 基于T细胞群体动力学，为优化免疫治疗方案提供理论框架。

提出的方法

• 构建了一套描述Th1、Th2与Treg细胞增殖及其相互抑制作用的非线性常微分方程组。
• 引入由Treg细胞产生的IL-10与TGF-β的细胞因子反馈环路，以模拟其免疫抑制功能。
• 应用闪烁映射（stroboscopic maps）分析周期性注射方案，并识别动力系统中的稳定不动点。
• 通过数值模拟比较不同剂量递增时间表下，传统与快速免疫治疗方案的治疗结果。
• 采用稳定流形理论等分析工具，表征系统的长期行为及向治疗性平衡态的收敛性。
• 基于Ruëff等人（2000年）的实验数据及临床观察中治疗时机与细胞浓度变化，校准模型参数。

实验结果

研究问题

• RQ1 与经典Th1-Th2模型相比，引入Treg细胞后，过敏原特异性免疫治疗的预测动力学如何改变？
• RQ2 高剂量过敏原给药在触发Treg扩增与Th2抑制中的作用是什么？
• RQ3 为何快速治疗方案尽管与传统方案具有相同的维持阶段，却能更早产生治疗效果？
• RQ4 该模型能否解释临床研究中观察到的Th1/Th2比值变化，作为Treg介导调控的结果？
• RQ5 在治疗过程中，Treg细胞开始主导并抑制Th2反应的关键时间点是什么？

主要发现

• 模型表明，以高剂量过敏原注射启动维持阶段是治疗成功的关键时刻，因其能迅速触发Treg的增殖。
• 在快速治疗方案中，Treg细胞在t = 5周时即开始超越Th2细胞，而在传统方案中这一现象仅在t = 20周时出现。
• 尽管启动时间不同，两种方案在维持阶段均收敛至相同的稳定周期轨道，表明最终疗效一致。
• 治疗期间Th1/Th2比值上升，提示Th1优势的出现，可能解释临床研究中观察到的“Th1-Th2转换”现象。
• 模型支持负反馈调节假说，表明高剂量抗原暴露可促进Treg扩增，从而抑制Th2驱动的过敏反应。
• 通过闪烁映射与稳定流形分析，成功识别出系统中的关键转变，特别是与免疫耐受相对应的稳定不动点的出现。